Hydroquinone Marketer Ceases Shipments After Warning From Texas
This article was originally published in The Rose Sheet
Obagi Medical is ceasing shipments of hydroquinone 4% products to doctors’ offices in Texas after the state's Department of State Health Services (DSHS) warned about compliance with federal and Texas laws.
You may also be interested in...
Keystone Labs agrees to cease manufacturing OTC drugs following a 2013 FDA warning letter and repeated GMP violations noted during inspections, including failure to investigate sources of contamination. Firm suggests it will continue making cosmetic hair- and skin-care formulas while outsourcing OTC product manufacturing.
The Cosmetic Ingredient Review Expert Panel plans to evaluate new data regarding the inhalation toxicity of benzyl alcohol and benzoic acid during its next panel meeting June 28-29
Disrupting the availability of hydroquinone skin-lightening products would represent an "overreaction" by FDA, according to a literature review published in the November issue of the Journal of the American Academy of Dermatology